Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Spark Capital Advisors(India) Private Limited
$35.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aurobindo Pharma Ltd Gets USFDA Nod For Anti-Diabetes Drug-Business Line


Thursday, 14 Feb 2013 04:33am EST 

Business Line reported that Aurobindo Pharma Ltd received approval from the US Food and Drug Administration to market anti-diabetes drug Pioglitazone tablets in the American market. The Company has received approval from the USFDA to manufacture and market Pioglitazone tablets and its earlier tentatively approved combination of Pioglitazone Hydrochloride and Metformin Hydrochloride tablets .The medicines are indicated as an addition to diet and exercise to improve glycemic control in adults with Type-2 diabetes mellitus. 

Company Quote

968.25
20.8 +2.20%
6:29am EDT